テネシーにおける小細胞肺がんの臨床試験
テネシー内の拠点で、小細胞肺がんに関する24件の研究が参加者を募集しています。
テネシー内の都市
公式研究テキスト（英語）
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT03460977A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
被験者募集中第1相
19歳以上 · 全性別 · 2026/10/01更新 · NCT06586957DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Baptist Cancer Center - Memphis, Memphis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07472517Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Vanderbilt University Medical Center, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06047379A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 280619, Knoxville
- University Of Tennessee Medical Center /ID# 279896, Knoxville
- Baptist Memorial Hospital /ID# 281405, Memphis
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07365241Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Sarah Cannon - Tennessee Oncology, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
- SCRI Oncology Partners, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT07325136A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- SCRI OP (Oncology Partners), Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/14更新 · NCT07218146A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- SCRI Oncology Partners, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06646276A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
- Sarah Cannon Research Institute ( Site 7001), Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06780137Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- West Cancer Center & Research Institute, Germantown
- University of Tennessee Medical Center, Knoxville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/01更新 · NCT06712355Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
被験者募集中第1/2相
18歳〜100歳 · 全性別 · 2026/08/27更新 · NCT06726148A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
- Sarah Cannon Research Institute (SCRI), Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/25更新 · NCT07488923Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
- Baptist Cancer Center, Memphis
被験者募集中第1相
18歳〜99歳 · 全性別 · 2026/08/21更新 · NCT07531095A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- SCRI Oncology Partners, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT06095505A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- THE WEST CLINIC, PLLC dba West Cancer Center, Germantown
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/06更新 · NCT06203210Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
- Tennessee Oncology, PLLC, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/24更新 · NCT06931626A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT06131840A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- Sarah Cannon Research Institute - Oncology Partners, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/09更新 · NCT07174583A Study of LY4175408 in Participants With Advanced Cancer
- Sarah Cannon Research Institute, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/23更新 · NCT07046923A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 136, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/21更新 · NCT05914116ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。